Wednesday, December 8, 2021, San Antonio, TX, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer (Part 2 of a 3-Part Series)

A CME Satellite Symposium Held in Conjunction with SABCS®2021

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom G-M (3rd floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, TX, preregistration is required as seating is limited.  
 
Faculty
Carey K Anders, MD
Professor of Medicine
Medical Director of the Duke Center of Brain and Spine Metastases
Duke Cancer Institute
Durham, North Carolina

Virginia F Borges, MD, MMSc
Professor of Medicine with Tenure
John C and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program and
Young Women’s Breast Cancer Translational Program
University of Colorado Cancer Center
Aurora, Colorado

Sara Hurvitz, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Santa Monica, California


Ian E Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Lisa Carey, MD
Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
Deputy Director of Clinical Sciences
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Puma Biotechnology Inc and Seagen Inc.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC)

MODULE 2: Optimizing the Management of HER2-Positive Metastatic BC

MODULE 3: Treatment of HER2-Positive Brain Metastases

MODULE 4: Future Directions in the Management of HER2-Positive Localized and Metastatic BC

MODULE 5: Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy

Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of a specific neoadjuvant therapeutic regimen for patients with HER2-overexpressing localized breast cancer (BC), and integrate this information into treatment decision-making.
  • Apply available research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized BC who received neoadjuvant treatment.
  • Evaluate published research data to guide the selection and duration of adjuvant and/or extended adjuvant therapy for patients with HER2-overexpressing localized BC.
  • Implement a long-term clinical plan for the management of advanced HER2-positive BC, incorporating existing and recently approved targeted agents and regimens.
  • Design an optimal approach to the clinical care of patients with HER2-positive BC and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive BC.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive BC, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr AndersConsulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Eisai Inc, Elucida Oncology Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Novartis, Seagen Inc; Contracted Research: G1 Therapeutics Inc, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, The Zion Pharma; Royalties: Jones and Bartlett Learning. Dr BorgesConsulting Agreement: Seagen Inc; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Merck, Pfizer Inc, Seagen Inc. Dr HurvitzContracted Research Paid to Institution: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CytomX Therapeutics, Daiichi Sankyo Inc, Dignitana AB, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks Inc. Dr KropConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celltrion, Context Therapeutics, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc, Taiho Oncology Inc; Contracted Research: Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.

MODERATORLisa Carey, MD – No relevant conflicts of interest to disclose.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Puma Biotechnology Inc and Seagen Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (3rd floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center.

 
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.